GeneralBreaking NewsBreakingLatest News
FSSAI Seeks Proof from Nestle, Abbott, and Zydus Over Infant Formula Claims
Sentiment: NeutralHigh Priority
What Happened?
The FSSAI has issued notices to Nestle, Abbott, and Zydus regarding claims made in advertisements for infant formula and Complan. The regulator seeks scientific evidence to support these claims.
Key points
- FSSAI issued notices to Nestle, Abbott, Nutricia, Mead Johnson, and Zydus over claims in advertisements.
- The regulator questions claims related to digestion, immunity, and growth in infants.
- Nestle is asked to substantiate claims about whey protein digestibility and immune system support.
- FSSAI flagged social media promotions of infant formulas as potentially violating regulations.
- Zydus Wellness faces scrutiny over Complan's claims of faster growth and cognitive benefits.
Key insights
- The scrutiny may lead to stricter regulations on infant nutrition advertising.
- Companies may need to invest more in substantiating their health claims.
- Potential legal consequences could arise if companies fail to comply with FSSAI's requests.
Why it matters
These notices could impact the marketing practices of major infant formula brands.
Entities
FSSAI· OrganizationNestle India· CompanyAbbott Healthcare· CompanyZydus Wellness· CompanyComplan· Product
Source
India Today
